Sanofi stops development of eczema drug amlitelimab after mixed trial results

Sanofi announced on Friday that it is halting further development of amlitelimab for atopic dermatitis, a drug it had once promoted as a potential successor to its blockbuster Dupixent.

The company had earlier indicated in January that it would seek approval despite mixed results from late‑stage studies and emerging safety signals. After a pipeline review, Sanofi concluded that the overall efficacy and safety data did not justify continued investment in the eczema indication.

The move follows recent decisions by Amgen and Kyowa Kirin to discontinue similar experimental medicines, underscoring the challenges of bringing new immune‑modulating therapies to market.

Sanofi said it will keep testing amlitelimab in celiac disease and expects to present data from a mid‑stage study by the end of the year.